Evidence map›Paper›PMID 40584265›Full record

ArticleJHEP reports : innovation in hepatology2025

The association between stage migration and overall survival after radiation-based therapies in patients with hepatocellular carcinoma.

Suraj Pai, Amit G Singal, Shengchen Hao, Sruthi Yekkaluri, Anjana Pillai, Andrew M Moon, Ted K Yanagihara, Nima Kokabi, Jane Brown, Vir J Kalaria and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Suraj PaiDivision of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA.
Amit G SingalDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Shengchen HaoDivision of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA.
Sruthi YekkaluriDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Anjana PillaiDepartment of Internal Medicine, University of Chicago, Chicago, IL, USA.
Andrew M MoonDivision of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, NC, USA.
Ted K YanagiharaUniversity of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
Nima KokabiDivision of Interventional Radiology, University of North Carolina, Chapel Hill, NC, USA.
Jane BrownSchool of Medicine, University of North Carolina, Chapel Hill, NC, USA.
Vir J KalariaSchool of Medicine, University of North Carolina, Chapel Hill, NC, USA.
Michael C MohnaskySchool of Medicine, University of North Carolina, Chapel Hill, NC, USA.
Jonathan Melendez-TorresDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Muhammad M TahirDepartment of Radiology, Beth Israel Deaconess, Boston, MA, USA.
Aamir AliDepartment of Radiology, Beth Israel Deaconess, Boston, MA, USA.
Muhammad S MalikDepartment of Radiology, Beth Israel Deaconess, Boston, MA, USA.
Isaiah BrownDepartment of Internal Medicine, University of Chicago, Chicago, IL, USA.
Mikin V PatelDepartment of Radiology, University of Chicago, Chicago, IL, USA.
Jared ChristensenDepartment of Radiology, University of Michigan, Ann Arbor, MI, USA.
Theodore LawrenceDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Mishal Mendiratta-LalaDepartment of Radiology, University of Michigan, Ann Arbor, MI, USA.
Alisa LikhitsupDivision of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA.
Ammar SarwarDepartment of Radiology, Beth Israel Deaconess, Boston, MA, USA.
Neehar D ParikhDivision of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Aims: Stereotactic body radiation therapy (SBRT) and transarterial radioembolization (TARE) are common locoregional therapies for hepatocellular carcinoma (HCC). However, lack of surrogate endpoints has limited the feasibility of conducting comparative effectiveness clinical trials. Methods: We conducted a multicenter retrospective cohort study of adult patients with HCC who received SBRT or TARE as initial treatment between 2008 and 2019. We excluded those with Barcelona Clinic Liver Cancer (BCLC) stage D disease. The primary outcome was overall survival, with transplantation as a competing risk. The independent variable of interest was stage migration to a more advanced BCLC stage ( Results: We included 257 patients with a median age of 65 years; 77% male and 66% White. Most (75%) had Child-Pugh class A cirrhosis. Stage migration within 6 months was observed in 45 (18%) patients. Patients who experienced stage migration within 6 months of receiving SBRT or TARE had significantly shorter survival than those without stage migration (median 192 days [IQR 108-397 days]) median Conclusions: Stage migration at 6 months is associated with overall survival in patients with HCC undergoing SBRT or TARE. Impact and implications: Stage migration in patients with receiving hepatocellular carcinoma (HCC) treatment is a multi-faceted measure of tumor function, functional status, and liver function. In this study we were able to show that worsening Barcelona Clinic Liver Cancer stage within 6 months of receipt of radiation treatment is associated with overall survival. Stage migration could be further explored as an endpoint in future clinical trials in patients with HCC receiving radiation therapies.

Indexed as

HCCSBRTTAREY90

Identifiers

PMID40584265
PMCPMC12205648

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.